The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity-Reference-Cited by-同舟云学术

The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity

Published:2019-10-30 Issue:7781 Volume:575 Page:217-223
ISSN:0028-0836
Container-title:Nature
language:en
Short-container-title:Nature

Author:

Canon Jude,Rex Karen,Saiki Anne Y.,Mohr Christopher,Cooke Keegan,Bagal Dhanashri,Gaida Kevin,Holt Tyler,Knutson Charles G.,Koppada Neelima,Lanman Brian A.,Werner Jonathan,Rapaport Aaron S.,San Miguel Tisha,Ortiz Roberto,Osgood Tao,Sun Ji-Rong,Zhu Xiaochun,McCarter John D.,Volak Laurie P.,Houk Brett E.,Fakih Marwan G.,O’Neil Bert H.,Price Timothy J.,Falchook Gerald S.,Desai Jayesh,Kuo James,Govindan Ramaswamy,Hong David S.,Ouyang Wenjun,Henary Haby,Arvedson Tara,Cee Victor J.,Lipford J. Russell

Publisher

Springer Science and Business Media LLC

Subject

Multidisciplinary

Link

http://www.nature.com/articles/s41586-019-1694-1.pdf

Reference33 articles.

1. Barbacid, M. ras genes. Annu. Rev. Biochem. 56, 779–827 (1987).

2. Simanshu, D. K., Nissley, D. V. & McCormick, F. RAS proteins and their regulators in human disease. Cell 170, 17–33 (2017).

3. Ostrem, J. M., Peters, U., Sos, M. L., Wells, J. A. & Shokat, K. M. K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions. Nature 503, 548–551 (2013).

4. Patricelli, M. P. et al. Selective inhibition of oncogenic KRAS output with small molecules targeting the inactive state. Cancer Discov. 6, 316–329 (2016).

5. Janes, M. R. et al. Targeting KRAS mutant cancers with a covalent G12C-specific inhibitor. Cell 172, 578–589 (2018).

Cited by 1506 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Multiscale calculations reveal new insights into the reaction mechanism between KRASG12C and α, β-unsaturated carbonyl of covalent inhibitors;Computational and Structural Biotechnology Journal;2024-12

2. Structural insights into small-molecule KRAS inhibitors for targeting KRAS mutant cancers;European Journal of Medicinal Chemistry;2024-11

3. Covalent small-molecule inhibitors of SARS-CoV-2 Mpro: Insights into their design, classification, biological activity, and binding interactions;European Journal of Medicinal Chemistry;2024-11

4. A NRAS mRNA G-quadruplex structure-targeting small-molecule ligand reactivating DNA damage response in human cancer cells for combination therapy with clinical PI3K inhibitors;International Journal of Biological Macromolecules;2024-11

5. Synthetic approaches and application of representative clinically approved fluorine-enriched anti-cancer medications;European Journal of Medicinal Chemistry;2024-10